Omic studies reveal the pathogenic lipid droplet proteins in non-alcoholic fatty liver disease

Protein Cell. 2017 Jan;8(1):4-13. doi: 10.1007/s13238-016-0327-9. Epub 2016 Oct 18.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is an epidemic metabolic condition driven by an underlying lipid homeostasis disorder. The lipid droplet (LD), the main organelle involved in neutral lipid storage and hydrolysis, is a potential target for NAFLD therapeutic treatment. In this review, we summarize recent progress elucidating the connections between LD-associated proteins and NAFLD found by genome-wide association studies (GWAS), genomic and proteomic studies. Finally, we discuss a possible mechanism by which the protein 17β-hydroxysteroid dehydrogenase 13 (17β-HSD13) may promote the development of NAFLD.

Keywords: 17β-HSD13; PNPLA3; genome-wide association study; lipid droplets; non-alcoholic fatty liver disease; proteomics.

Publication types

  • Review

MeSH terms

  • 17-Hydroxysteroid Dehydrogenases* / genetics
  • 17-Hydroxysteroid Dehydrogenases* / metabolism
  • Animals
  • Genome-Wide Association Study
  • Genomics*
  • Humans
  • Lipid Droplets / metabolism*
  • Lipid Metabolism / genetics*
  • Non-alcoholic Fatty Liver Disease* / genetics
  • Non-alcoholic Fatty Liver Disease* / metabolism
  • Proteomics*

Substances

  • 17-Hydroxysteroid Dehydrogenases